share_log

利民股份(002734.SZ):目前公司原药产能为10.27万吨,制剂产能为11.44万吨

limin group (002734.SZ): Currently, the company's API production capacity is 0.1027 million tons, and the formulation production capacity is 0.1144 million tons.

Gelonghui Finance ·  Sep 11, 2024 02:32

Gelonghui, September 11 | Limin Co., Ltd. (002734.SZ) said on the investor interactive platform that the company has advantages in the entire biological fermentation, biological semisynthesis, and formulation processing industry chain, and has advanced biological fermentation technology, chemical synthesis technology, and formulation compatibility technology, making product cost, quality and supply advantages. Currently, the company's original drug production capacity is 0.1027 million tons, and the formulation production capacity is 0.1144 million tons. In 2023, the company's production capacity utilization rate was 68.35% for the original drug and 85.28% for the formulation. In the first half of this year, raw drug production increased 16.59% year on year, and formulation production increased 19.32% year on year.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment